<DOC>
	<DOCNO>NCT00409929</DOCNO>
	<brief_summary>This study evaluate safety tolerability ascend single oral dos great 500 mg AEB071 healthy subject</brief_summary>
	<brief_title>A Study Evaluate Safety , Tolerability , Pharmacokinetics , Pharmacodynamics AEB071</brief_title>
	<detailed_description />
	<criteria>Male and/or female subject 1855 year age good health determine past medical history , physical examination , vital sign , electrocardiogram laboratory test screen . Female subject either surgically sterilize postmenopausal . Smokers Use prescription drug overthecounter medication within 2 week prior dose , 2 month inducer inhibitor cytochrome CYP4503A4 ( paracetamol acceptable ) Donation loss 400 mL blood within 8 week prior dose A past medical history clinically significant ECG abnormality family history prolong QTinterval syndrome History History fainting , hypotension standing , arrhythmia , acute chronic bronchospastic disease History clinically significant drug allergy ; atopic allergy know hypersensitivity study drug drug similar study drug Any surgical medical condition might significantly alter absorption , distribution , metabolism excretion drug may jeopardize subject case participation study History immunocompromise ( include positive HIV test result ) drug alcohol abuse within 12 month prior dose evidence abuse current positive Hepatitis B surface antigen ( HBsAg ) Hepatitis C test result . Additional protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>Safety , tolerability , pharmacokinetics , pharmacodynamics , AEB071 , healthy subject , transplantation</keyword>
</DOC>